Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer

Next Previous
X
Search
Trial Profile

A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TCR T cell therapy (Primary) ; Aldesleukin; Cyclophosphamide; Filgrastim; Fludarabine; Mesna
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Advanced breast cancer; Brain metastases; Colorectal cancer; Gastrointestinal cancer; Glioblastoma; Lung cancer; Non-small cell lung cancer; Ovarian cancer; Squamous cell cancer; Urogenital cancer
  • Focus First in man; Therapeutic Use

    • Most Recent Events

    • 08 Mar 2024 Planned initiation date changed to 7 Mar 2024.
    • 08 Mar 2024 Planned End Date changed from 31 Dec 2029 to 8 Mar 2024.
    • 08 Mar 2024 Planned primary completion date changed from 31 Dec 2028 to 8 Mar 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top